Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Canadian drug regulatory framework.

L Kelly1, M Lazzaro, C Petersen

  • 1CNSD, BCANS, Therapeutic Products Directorate, Tunney's Pasture, Ottawa, ON, Canada.

The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques
|May 2, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metal contamination in mice under conventional husbandry.

Toxicology letters·2026
Same author

Sodium Glucose Co-transporter 2 Inhibitor associated perioperative Diabetic Ketoacidosis.

Irish medical journal·2026
Same author

Protracted postpartum urinary retention: risk factors, treatment, and effect on pelvic floor dysfunction.

Irish medical journal·2025
Same author

Vascularised Composite Allotransplantation - A guide to optimal dissemination of scientific outputs.

Journal of hand and microsurgery·2025
Same author

Systematic review - Adjuvant radiotherapy of the vulva in primary vulvar cancer.

Gynecologic oncology·2024
Same author

Effect of Indian clubbell exercises on cricket fast bowlers' shoulder kinematics.

South African journal of sports medicine·2024
Same journal

Practice Patterns and Care Gaps in Lennox Gastaut Syndrome: A call for Action.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
Same journal

Isolated Achiasma Discovered at Age 86: A Rare Cause of see-saw nystagmus and bitemporal hemianopia.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
Same journal

Post-Stroke Parakinesia Brachialis Oscitans: Clinical Insights from a Case Series.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
Same journal

A Neuronal Perspective.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
Same journal

Diagnostic efficacy, costs, and safety of portable ultra-low field MRI in brain imaging: a systematic review.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
Same journal

Chronology of Non-Motor Symptoms in 100 Patients with Advanced PD of 10 Years' Duration: Pre- versus Post-Motor Period.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
See all related articles

Canadian drug submission evaluators assess data to recommend drug benefits and risks. This document outlines the regulatory framework for drug authorization, covering Health Canada

Area of Science:

  • Regulatory Science
  • Drug Evaluation
  • Health Policy

Background:

  • Regulatory drug submission evaluators in Canada critically assess submitted data and sponsor interpretations.
  • Assessments aim to provide evidence- and context-based recommendations on potential drug benefits and risks.
  • This involves understanding the role of the sponsor and Health Canada's responsibilities under the Food and Drugs Act.

Purpose of the Study:

  • To outline the regulatory framework for drug marketing authorization in Canada.
  • To define the distinction between regulatory and physician authorization for drug use.
  • To highlight factors influencing the review process for drug submissions.

Main Methods:

  • Review of the regulatory framework governing drug authorization in Canada.

Related Experiment Videos

  • Analysis of organizational, process, and legal factors within Health Canada.
  • Consideration of international guidelines and decisions from other jurisdictions.

    • Main Results:

    • Drug authorization requires accurate Product Monograph wording reflecting current safety and efficacy data.
    • Hypothesis-confirming studies are essential for regulatory endorsement.
    • Specific challenges exist in reviewing dementia therapies, including preventative vs. symptomatic treatments and disease-modifying effects.

    Conclusions:

    • The Canadian regulatory framework ensures rigorous assessment of drug submissions.
    • Clear distinctions exist between regulatory and physician authorization.
    • Ongoing issues in drug review necessitate careful consideration of trial design, statistical methods, and therapeutic effects.